BiotechTube

ION582 + Placebo

Phase 3Recruiting
0 watching 0 views this week📈 Rising
74
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Angelman Syndrome

Conditions

Angelman Syndrome

Trial Timeline

Jun 10, 2025 → Apr 1, 2030

NCT ID
NCT06914609

About ION582 + Placebo

ION582 + Placebo is a phase 3 stage product being developed by Ionis Pharmaceuticals for Angelman Syndrome. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06914609. Target conditions include Angelman Syndrome.

Hype Score Breakdown

Clinical
27
Activity
18
Company
7
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT06914609Phase 3Recruiting

Competing Products

9 competing products in Angelman Syndrome

See all competitors
ProductCompanyStageHype Score
RO7248824RochePhase 1
33
RO7248824RochePhase 1
33
AlogabatRochePhase 2
52
ION582Ionis PharmaceuticalsPhase 1/2
38
GTX-102Ultragenyx PharmaceuticalPhase 3
72
GTX-102Ultragenyx PharmaceuticalPhase 3
72
GTX-102Ultragenyx PharmaceuticalPhase 2
47
GTX-102Ultragenyx PharmaceuticalPhase 1/2
36
NNZ-2591Neuren PharmaceuticalsPhase 2
47

Other Products from Ionis Pharmaceuticals

InotersenPhase 3
74
ISIS 3521 + carboplatin + paclitaxelPhase 3
74
DonidalorsenPhase 3
74
mipomersen sodium + placeboPhase 3
74
Olezarsen + PlaceboPhase 3
74